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A growing body of evidence suggests that the human gut microbiota plays a role in the development 
of obesity and related metabolic diseases. However, there is little consensus between studies, which 
could be due to biological as well as technical variation. In addition, little human data are available 
to investigate whether tissue-specific insulin sensitivity is related to specific microbial patterns. We 
examined this relation in two independent cohorts of overweight and obese pre-diabetic men, using 
phylogenetic microarray data and hepatic, peripheral and adipose tissue insulin sensitivity that were 
determined by a two-step hyperinsulinemic-euglycemic clamp with [6,6-2H2]-glucose tracer infusion. 
Despite a prominent subject-specific microbiota, we found significant associations of microbial taxa 
with tissue-specific insulin sensitivity using regression analysis. Using random forests we found 
moderate associations with other measures of glucose homeostasis in only one of the cohorts (fasting 
glucose concentrations AUC = 0.66 and HbA1c AUC = 0.65). However, all findings were cohort-specific 
due to pronounced variation in microbiota between cohorts, suggesting the existence of alternative 
states for dysbiosis in metabolic syndrome patients. Our findings suggest individual or group related 
dynamics, instead of universal microbiota signals, related to the host when the overweight or obese 
state has already developed and argue that care should be taken with extrapolating significant 
correlations from single cohorts, into generalized biological relevance.
There is increasing evidence to suggest that our gut microbiome is associated with the development of obesity, 
insulin resistance and type 2 diabetes. This concept was first described in studies, in which germ-free mice showed 
less adiposity, improved insulin sensitivity and glucose tolerance as compared to conventionalized mice1–4. Later 
studies showed that the microbiota composition differs between lean, obese and diabetic mice and humans5–8. 
Microbial analyses of large genome-wide association studies showed that patients with type 2 diabetes are charac-
terized by a decrease in the abundance of universal butyrate-producers and an increase in various opportunistic 
pathogens5,6,9. Nevertheless, between studies there is an overall lack of consistency regarding the identified micro-
bial biomarkers and putative mechanisms underlying the observations. Discrepancies between studies could be 
a result of the heterogeneity of groups, genetic background, habitual lifestyle, diet and the methodology used by 
different researchers10. Meta-analyses have shown that individuals could be classified based on their microbiota 
as lean or obese with statistically significant accuracy within a study, consistent with the observation that this phe-
notype can be experimentally transferred in mice by microbiota transplantation8. However, microbial signatures 
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were not consistent between studies even when the data were analysed in the same way11. Furthermore, the com-
parison of discriminant metagenomic markers for type 2 diabetes in European women5 and Chinese individuals9 
revealed cohort specific differences, and the authors concluded that metagenomic predictive tools for type 2 
diabetes should be specific for the age and geographical location of the populations studied5. Correspondingly, 
another putative marker for obesity based on the gut microbiome, the Bacteroidetes to Firmicutes ratio (B:F) 
proposed by Ley et al.7, remains controversial as it has been both refuted12 and contradicted13.
Nevertheless, transplantation of the microbiota in rodents and humans has provided evidence for the causal 
role of the microbiota in adiposity and metabolic health. Fecal transplantation from obese into germ-free mice 
significantly increased adiposity8,14, and fecal transplantation from lean donors into metabolic syndrome patients 
altered the recipients’ microbiota composition with a concomitant, minor improvement in peripheral insulin 
sensitivity based on responders and non-responders15. These observations were confirmed in a larger population, 
however the effect was also shown to be transient. Nevertheless, the authors identified a bacterial signature at 
baseline that was predictive for responder status16. In contrast, it has recently been demonstrated that interference 
with adult microbiota by 7-day antibiotic treatment has no clinically relevant impact on host metabolism in obese 
humans, despite deviant microbiota17. Importantly, the relationship between gut microbiota and tissue-specific 
insulin action has never been established in obese humans. Here, we investigated the relationship between the gut 
microbiota composition and adipose tissue, muscle and liver insulin sensitivity by means of the gold-standard 
two-step hyperinsulinemic-euglycemic clamp with [6,6-2H2]-glucose tracer infusion in two independent Dutch 
cohorts of overweight and obese pre-diabetic males from the Maastricht (MAA) and Amsterdam (AMS) region 
of the Netherlands.
Results
Subject characteristics. The subjects’ characteristics, including insulin resistance measurements are shown 
in Table 1. Subjects in both the MAA and AMS cohorts were insulin resistant (Homeostatic model assessment of 
insulin resistance (HOMA-IR): 4.5 ± 0.2 and 5.1 ± 0.3 respectively, ns). MAA presented with higher fasting glu-
cose concentrations (6.1 ± 0.01 vs. 5.8 ± 0.09 mmol/l, p < 0.05), whereas insulin concentrations were lower than 
in AMS cohort (16.8 ± 0.8 vs. 20.0 ± 1.2 mU/l, p < 0.05). Homeostatic model assessment for beta-cell function 
(HOMA-B) was lower in MAA than in AMS (136.3 ± 7.5 vs. 192.0 ± 15.3%, p = 0.001). From the MAA cohort, 2 
subjects had missing data for glycated haemoglobin (HbA1c), 2 for: insulin-mediated glucose disposal (Rd), 6 for 
% suppression of Endogenous Glucose Production (EGP) and 1 for % suppression of free fatty acids (FFA). For 
the AMS cohort there were no missing variables.
Notably, clamp procedures were slightly different between centers (see Methods), and thus, potential differ-
ences in peripheral, hepatic and adipose tissue insulin sensitivity values between cohorts were not assessed.
fecal microbiota composition. Remarkably, the average microbiota composition in both cohorts showed 
pronounced differences (Fig. 1). While Actinobacteria (Bifidobacterium and Propionibacterium) were more abun-
dant in the MAA cohort, mainly genus-like groups of Clostridium clusters IV and XIVa were more abundant in 
the AMS cohort. More specifically, Sporobacter termitidis et rel. (IV), Papillibacter cinnamivorans et rel. (IV), 
Subdoligranulum variable et rel. (IV), Anaerotruncus colihominis et rel. (IV), Butyrivibrio crossotus et rel. (XIVa) 
and Clostridium symbiosum et rel. (XIVa), of which the latter four are known to contain butyrate-producing 
species, were more abundant in AMS than in MAA (Fig. 1). In addition, Uncultered Clostriales I and II were 
more abundant in AMS. A complete overview of the differential abundance of all detected taxa can be found in 
supplementary table 1.
MAA (n = 56) 
Maastricht
AMS (n = 42) 
Amsterdam
Age 59.1 ± 1.0 54.9 ± 1.1
Weight (kg) 96.5 ± 1.3 116.3 ± 2.0
BMI (kg/m2) 31.2 ± 0.4 34.8 ± 0.5
Waist/hip ratio 0.95 ± 0.01 1.05 ± 0.01
Fasting insulin (mU/ml) 16.80 ± 0.79 20.02 ± 1.24
Fasting glucose (mmol/l) 6.06 ± 0.07 5.76 ± 0.09
HOMA-IR 4.5 ± 0.2 5.1 ± 0.3
HOMA-B% 136.3 ± 7.5 192.0 ± 15.3
HbA1c (%) 5.58 ± 0.05 5.74 ± 0.05
Fasting TAG 1.30 ± 0.10 1.50 ± 0.11
Rd (umol*kg-1*min-1)* 23.34 (10.7–51.4) 26.1 (10.1–40.0)
Suppression EGP (%)* 44.1(17.4–79.1) 55.6 (30.8–85.0)
Suppression FFA (%)* 45.3(−6,1–84.1) 74.4(53.9–92.1)
Table 1. Subjects’ characteristics. HOMA-IR: homeostasis model assessment for insulin resistance, HOMA-B%: 
homeostasis model assessment for beta-cell function, HbA1c: glycated haemoglobin, TAG: triacylglycerol, 
Rd: rate of disappearance, EGP: endogenous glucose production by the liver, FFA: free fatty acids. Data 
are expressed as mean ± SEM. Clamp-results are expressed as mean (range). *due to differences in clamp 
procedures (see Methods) between centers, no statistical comparison was made between cohorts.
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Principal component analysis (PCA) analysis of the microbiota composition and calculation of within cohort 
Pearson correlations demonstrated that the variation between subjects from MAA was significantly higher than 
those from AMS (<2.2e-16, two-sided t-test, Supplementary Fig. 1) (Fig. 2). Although the majority of subjects 
from MAA overlapped in composition with those of AMS, it is remarkable that approximately 1/3 of MAA 
showed a distinct composition from this group along the first principal component. This explains the remarkable 
difference average microbiota composition between the two cohorts. Moreover, it suggests that some metabolic 
Figure 1. Enrichment of bacterial taxa in two separate cohorts of obese men. Genus like bacterial groups which 
showed significantly different abundance (Log10 signal intensity) between the two cohorts. The left side shows 
taxa enriched in AMS right side taxa enriched in MAA.
Figure 2. Principle component analysis of the fecal microbiota composition of 85 overweight insulin resistant 
overweight males from Maastricht (MAA) and Amsterdam (AMS). Individuals from AMS and a subset from 
MAA overlap and a second group of individuals in MAA was observed as indicated by the right ellipse. These 
also show associations with the two metabolic parameters associated with microbiota composition in MAA 
through Random Forests analysis. The direction of the species arrows depicts the abundance of microbial 
groups. Length of the arrows is a measure of fit. The environmental variable arrows approximate the correlation 
between species and an environmental variable. The further a sample falls in the direction indicated by the 
arrow, the higher the correlation. Samples near the coordinate origin (zero point) suggest near zero correlation.
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syndrome patients from MAA exhibit an alternative state of microbiota composition compared to the overlapping 
AMS and MAA individuals.
correlations between microbiota composition and host metabolic parameters. Tissue-specific 
insulin sensitivity. After correction for multiple testing, peripheral, hepatic and adipose tissue insulin sensitiv-
ity (Rd, % suppression of EGP and % suppression of FFA, respectively), did not significantly correlate (q < 0.2) 
with the abundance of bacterial taxa at the genus like level in either cohort (Fig. 3). However, when adjusted for 
age, body mass index (BMI) and waist/hip ratio, several taxa did significantly correlate with Rd and % suppres-
sion of EGP in both cohorts (Fig. 3). Overall, the number of significant taxa with significant associations was 
higher in MAA. For both cohorts the number of significant correlations was dependent on the covariate, but in 
AMS all significant correlations were positive, while in MAA they were mostly negative, except for Atopobium, 
Actinomycetaceae, Collinsella, Bifidobacterium and Lactobacillus gasseri et rel. correlating with hepatic insulin sen-
sitivity (% suppression of EGP). None of these associations were replicated in the other cohort, while several groups 
from the Bacteroidetes Phylum; Prevotella tannerae et rel., Bacteroides spp (B. vulgatus, B. intestinales and B. ovatus) 
showed an opposite association in both cohorts (positive in AMS, negative in MAA). Moreover, the overall pattern 
of correlations of specific taxa with tissue-specific insulin sensitivity was distinctly different in both cohorts (Fig. 3).
In addition, we determined non-linear multivariate relationships between the microbiota composition and 
tissue-specific insulin sensitivity. To this end, we ordered each dataset in quartiles of insulin sensitivity (Rd, 
%EGP and %FFA) and used random forest classifiers to determine whether the bacterial composition was related 
to these markers of tissue-specific insulin sensitivity, by using the highest and lowest quartiles as classes (sup-
plementary Table 2). Both cohorts showed random classification for peripheral, liver and adipose tissue insulin 
sensitivity, indicating no significant relationship between microbial profiles and tissue-specific insulin sensitivity 
(data not shown).
Figure 3. Correlation-heatmaps of host metabolic parameters and microbiota abundance. Heatmaps of 
(partial) Spearman correlations of tissue-specific insulin sensitivity and other markers of glucose homeostasis 
with individual genus like bacterial groups for AMS and MAA. Spearman correlations were adjusted for age, 
BMI and waist/hip ratio. Blue show negative correlations and red positive. A ‘ + ’ depicts correlations with a 
corrected p-value of q < 0.2.
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Other measures of glucose homeostasis and insulin sensitivity. Except for the correlation of Peptococcus niger et 
rel. with HbA1c (ρ 0.57, p = 5.52E-05, q = 0.06) in the MAA cohort, no significant correlation (q < 0.2) was found 
between abundance of specific microbial groups and HOMA-IR, HOMA-B, fasting glucose or insulin concentra-
tions in either of the two cohorts (Fig. 3). However, again after correcting for age, BMI or waist/hip ratio several 
taxa did significantly correlate with other measures of glucose homeostasis. This time some significant correla-
tions were replicated in both cohorts: Clostridium colinum et rel. negatively correlated with HOMA-IR and B. 
vulgatus et rel. negatively with fasting glucose. However, the same number of significant associations showed an 
opposite trend; Actinomycetaceae with fasting glucose (positive in AMS and negative in MAA) and Oscillospira 
guillermondii et rel. with HbA1c (negative in AMS and positive in MAA). Besides the replicated and opposite 
associations, the overall pattern of correlation of specific taxa with measures of glucose homeostasis was distinctly 
different in both cohorts (Fig. 3).
Similar to the tissue-specific insulin sensitivity, we ordered each dataset in quartiles of fasting glucose and 
insulin, HOMA-IR, HOMA-B and HbA1c and used random forest classifiers to determine whether the bacterial 
composition was related to these markers, by using the highest and lowest quartiles as classes (supplementary 
Table 2). Random Forests is a supervised machine learning technique, which can utilize nonlinear relationships 
and complex dependencies between genus-like groups to identify bacterial taxa that differentiate the faecal com-
munity composition of individuals that are in the highest or lowest range of each host parameter, respectively. 
The measure of the success of the method is its ability to classify samples correctly. Random classification (always 
choosing 1 class would yield a classification error of 0.5, therefore, the performance should be higher if the input 
values or predictors (relative abundance of bacterial taxa) assist in classification. Only MAA showed a moderate 
improvement over random classification for individuals with the highest and lowest 25% of fasting glucose con-
centrations with an Area Under the Curve (AUC) of 0.66 or HbA1c 0.65. with taxa from Clostridium clusters IV 
(Faecalibacterium prausnitzii et rel. and Butyrivibrio crossatus et rel.) and XIVa (Roseburia intestinalis, Clostridium 
nexile and Eubacterium rectale and related species) and several Proteobacteria (Enterobacter aerogenes et rel. and 
Vibrio) as the most important microbiota prediction features for classification of individuals with high or low 
fasting glucose concentrations (Fig. 4). For HbA1c similar bacterial orders were among the most important taxa. 
However, different members of these higher phylogenetic groups were identified, such as for Clostridium clusters 
IV (Oscillospira guillermondii et rel., Sporobacter termitidis et rel., Faecalibacterium prausnitzii et rel.) and IX 
(Peptococcus niger et rel.) as well as Proteobacteria (Novosphingobium, Vibrio and Aeromonas) (Fig. 4).
Discussion
The aim of this cross-sectional study was to determine the relation between microbiota composition and 
tissue-specific insulin-sensitivity in two independent cohorts of obese males with ranging levels of insulin 
resistance. To our knowledge, this is the first observational study that considers hyperinsulinemic-euglycemic 
clamp-derived data, known to be the gold standard for determination of insulin sensitivity. In two independent 
cohorts of obese and overweight subjects, we assessed peripheral, hepatic and adipose tissue insulin sensitivity 
using a two-step hyperinsulinemic-euglycemic clamp in combination with a [6,6-2H2]-glucose tracer infusion. 
Figure 4. Top ten genus level groups with predictive power in classifying patients from MAA into the lowest 
and highest quartile of HbA1c (A) and fasting glucose (B). The higher the group the more the prediction power 
will be reduced when the specific group is removed from the Random Forests model. Taxa in red belong to the 
phylum Proteobacteria and taxa in green are butyrate producing Firmicutes.
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Only after correcting for several covariates, we found some associations between microbial taxa and adipose 
tissue, liver or skeletal muscle insulin sensitivity. However, the pattern of correlations was very distinct for each 
cohort and even showed significant associations with an opposite direction in each cohort. This might indicate 
that predicting the role of microbiota based on baseline compositional data in host insulin sensitivity is challeng-
ing when the obese state has already developed. In line with this, the significant correlations between surrogate 
measures of insulin sensitivity and glycemic control and gut microbiota composition, were very different in both 
cohorts, with even opposite directions of correlations. This showed that we could not identify a similar pattern 
of correlations between MAA and AMS or conserved associations between bacterial abundance and markers of 
tissue-specific insulin sensitivity (e.g. consistent identical direction of a correlation between a taxon with a met-
abolic parameter in both cohorts), because both cohorts showed highly divergent patterns. For instance, several 
Bacteroides species (vulgatus, intestinales and ovatus) showed conflicting correlations with hepatic insulin sensi-
tivity (% suppression of EGP) in both cohorts, highlighting the challenges associated with baseline observations 
in a single (non-intervention) cohort.
To gain more insight into these differing patterns we applied random forest classification of quartiled host 
parameters. Overall, in both cohorts the microbiota composition at genus level showed performance that was 
close to random classification, with differences in predictors as well as classification accuracy between these 
cohorts. To this end, only MAA showed a moderate improvement over random classification for fasting glucose 
and HbA1c. The most important microbiological feature for the prediction of HbA1c in MAA was the abundance 
of Peptococcus niger et rel. whose association was also identified using linear regression, underscoring the need for 
complementary analytical approaches. Among important microbiota features were several taxa that are known 
to produce butyrate18. These observations are in line with previous studies that showed a decreased abundance 
of some universal butyrate-producing bacteria and an increase in Lactobacillus and various opportunistic path-
ogens, associated with type 2 diabetes in a cohort of European women5,6 and Chinese individuals9. More impor-
tantly these authors also showed that the discriminant metagenomic markers for type 2 diabetes differed between 
the cohorts and concluded that, metagenomic predictive tools for type 2 diabetes should be specific for the age 
and geographical location of the populations studied5. The obvious differences in observations between the 
cohorts and the fact that the identified associations of peripheral and hepatic insulin sensitivity and other mark-
ers of glucose homeostasis, with specific gut microbiota members were very distinct for each cohort, illustrate 
that findings may differ from one cohort to another and confirm the observations by Karlsson and co-authors5.
Remarkably, before adjusting for any covariates in both cohorts no relationships between microbial compo-
sition and tissue-specific insulin sensitivity, as determined by state-of-the-art clamp techniques, were detected 
in both cohorts. Only after correction for covariates, such as age, BMI and waist/hip ratio numerous signifi-
cant associations (q < 0.2) were found. Previous studies have indicated a differential microbial composition in 
type 2 diabetes or impaired glucose tolerant subjects, but this was based on comparisons with individuals that 
exhibited normal glucose tolerance5,6,9,19. In contrast, the individuals in this study were all overweight, showed 
impaired glucose metabolism (impaired fasting glucose and/or impaired glucose tolerance) or had the metabolic 
syndrome, therefore it might be possible that the role of the microbiota is altered when a metabolically compro-
mised state has already developed, thus playing a more prominent role in the initial development of an impaired 
metabolic health than in the further development towards type 2 diabetes and cardiometabolic complications. 
Nevertheless, our populations exhibited a wide range of (tissue-specific) insulin sensitivity, ranging from normal 
to a considerably impaired insulin sensitivity.
On top of these observations, there were striking differences between the microbiota compositions of both 
cohorts, which were mainly linked to a subset of individuals (Fig. 2). Compared to AMS, the abundance of bifido-
bacteria was higher MAA, which has been linked to a healthier phenotype, a reduction in inflammatory markers 
and an improvement in glucose homeostasis and lipid metabolism20,21. However, a random forests based pre-
dictive model for type 2 diabetes, identified several Bifidobacterium species as highly predictive and enriched 
in type 2 diabetes in a Chinese, but not in a Swedish cohort5. Another difference between both cohorts was a 
lower abundance of specific taxa belonging to Clostridium cluster XIVa in MAA, which included known butyrate 
producers (e.g. Butyrivibrio crossotus and Clostridium symbiosum and related species)18. Also, there were several 
slight differences in metabolic profiles between both cohorts, with lower triacylglycerol (TAG) and glucose con-
centrations as well as a reduced HOMA-B in MAA. Although lower abundances of butyrate-producing bacteria 
have previously been reported in type 2 diabetes subjects in various states of insulin resistance5, these composi-
tional and metabolic differences were not linked in a significant way.
The strikingly cohort-specific observations suggest that the relation between microbiota composition and type 
2 diabetes as well as other characteristics of the metabolic syndrome is very dependent on the selected cohort of 
patients and their respective baseline microbiota composition. Similar observations have been made by other 
researchers as well5,11. In addition, it could be that alterations in microbiota composition are differently associated 
with the insulin resistance phenotype when the overweight and/or obese state of the patient is already established, 
as is the case for our metabolic syndrome patients. In the latter case we cannot exclude that the composition of the 
fecal microbiota may play a role in the worsening of insulin sensitivity in an early stage in the development from 
a lean towards an overweight/obese phenotype.
With regards to the difference in composition between the cohorts, the human microbiota is highly indi-
vidual, which we also clearly observed in our PCA plot (Fig. 2). Although we know its composition is impacted 
by numerous external as well as host-specific factors, including diet, age, antibiotics use, BMI, gender, and gen-
otype22,23, the interplay of variables that give rise to the variation of the microbiota is not yet fully understood 
because of its complexity and the influence of numerous stochastic variables, such as common exposures over 
a timeframe of years22. Nevertheless, the multitude of these variations and their combinations may explain why 
individual-specific (dysbiotic) microbiota profiles are continuously observed.
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This individuality of the microbiota composition may also explain why fecal transplantation from lean donors 
to recipients with the metabolic syndrome slightly improved peripheral insulin sensitivity only in a subgroup of 
subjects (metabolic responders), whereas other individuals did not show any effect on these parameters upon the 
intervention15. A follow-up study consisting of the individuals of the AMS cohort presented here, confirmed these 
observations in a larger population, however the effect was also shown to be transient, as both the microbiota and 
the metabolic parameters returned to baseline 18 weeks post transplant. Furthermore, the authors identified a 
panel of bacterial species whose abundance at baseline could predict the responder status with high accuracy16. 
Although the driving factors are currently unknown, they speculate that the level of metabolic response might 
be due to specific donor-host interactions. This shows that a difference of associations of microbial taxa with 
metabolic features between cohorts, does not automatically mean that a treatment for subsets of individuals, such 
as microbial transplant with a specific composition that are needed to shift an individual microbial ecosystem 
towards eliciting a metabolic response, cannot be predicted based on baseline composition.
The strength of the present study is the detailed phenotyping of study participants regarding glucose homeosta-
sis and insulin sensitivity, since we evaluated tissue specific insulin sensitivity with hyperinsulinemic-euglycemic 
clamp-derived data. Limitation of this study are its cross-sectional design limiting causal implications and a lack 
of information on other microbiota covariates such as diet.
Our study demonstrated that longitudinal studies are required to investigate the relation between fecal micro-
biota composition and insulin sensitivity in phenotypes varying in adiposity and insulin sensitivity. Such studies 
should also address microbial function to reveal if a microbial- or host component, or both can be found with 
predictive power.
Currently, we have no clear explanation of the remarkable difference between the two cohorts with respect 
to microbiota composition as well as the associations between microbial profiles and host metabolic parameters. 
Both cohorts included subjects with an increased risk for type 2 diabetes mellitus and/or metabolic syndrome in 
geographically closely located areas in the Netherlands (~150 km distance). It is striking that the general micro-
biota compositional variation of MAA only partly overlapped with AMS and that a subgroup-specific microbiota 
was only observed in MAA. We hypothesize that a subset of the metabolic syndrome patients of this cohort 
exhibit an alternative state of microbiota composition that is driven by a yet unknown force which is only present 
in this cohort. Nevertheless, this study clearly demonstrates that cohort-specific microbiota differences hamper 
finding a consensus biological interpretation between studies based on single baseline cohort observations. This, 
combined with the complexity of individual disease pathogenesis, as well as the individual-specific differences in 
microbiota composition, may explain the inconsistency in observations between different studies concerning the 
identification of signature microbes for obesity, as well as other disorders and diseases including inflammatory 
bowel disease and irritable bowel syndrome24–26.
conclusion
In the present study, tissue-specific insulin sensitivity, at the level of the adipose tissue, liver and skeletal muscle 
showed cohort specific correlations with the abundance of microbial genus-level groups in two cohorts of obese, 
insulin resistant males at baseline. With respect to the surrogate measures for insulin sensitivity and measures of 
glycemic control HbA1c and fasting glucose, the fecal microbiota composition showed predictive potential, but 
only in one of the cohorts. These latter findings stress the importance of taking metabolic profiles, environmental, 
genetic and microbial variables into account in future studies. Overall, our data combining detailed information 
on microbial composition and the insulin sensitivity phenotype in two cohorts, indicated that predictions regard-
ing the role for gut microbiota in host tissue-specific insulin sensitivity after development of the obese, insulin 
resistant state are difficult to extrapolate based on baseline microbiota composition alone.
Methods
Study population. We investigated baseline microbiota composition in relation to tissue-specific insulin 
sensitivity and other indicators of glucose metabolism in two independent cohorts of overweight and obese 
(BMI 25–45 kg/m2) Caucasian men between 35–70 years old (ClinicalTrials.gov NCT02241421 and Dutch Trial 
Register NTR2705). The cohort from Maastricht (MAA) consisted of 56 low-active (<3 hr organized sports activ-
ities per week), weight-stable (<2 kg body weight change 3 months prior to inclusion) subjects with impaired 
fasting glucose levels (IFG, glucose concentration ≥ 5.6 mmol/l) and/or impaired glucose tolerance (IGT, 2 h 
plasma glucose during a 75 g oral glucose tolerance test 7.8–11.1 mmol/l. Exclusion criteria were the use of anti-
biotics for a period of 3 months before entering the study; cancer; liver malfunction, known allergic reactions to 
any type of antibiotics; hearing disorders; major illnesses with a life expectancy less than 5 years and pulmonary 
hepatic, cardiovascular, kidney, and gastrointestinal disease. Subjects did not use lipid- and glucose-lowering 
drugs, beta-blockers, anti-oxidants or chronic corticosteroids17. The cohort from Amsterdam (AMS) consisted of 
42 subjects diagnosed with the metabolic syndrome according to the NCEP criteria: (≥3/5: fasting plasma glu-
cose ≥ 5.6 mmol/l, triglycerides ≥ 1.7 mmol/l, waist-circumference> 102 cm, high-density lipoprotein (HDL-) 
cholesterol <1.03 mmol/l, blood pressure ≥ 130/85 mmHg), were treatment naive and otherwise healthy16,27. 
Exclusion criteria were a cardiovascular event, history of recent weight loss, cholecystectomy and the use of any 
medication known to influence gut microbial composition in the last three months (including antibiotics and 
pre-/pro-/synbiotics and proton pump inhibitors) or targeting metabolic diseases (e.g., anti-diabetic, lipid-low-
ering and/or drugs). Subjects were recruited by newspaper advertisement in their consecutive regions and gave 
written informed consent before participation after reading the study protocol. For the study from Amsterdam 
the protocol was reviewed and approved by the Institutional Review Board of the Academic Medical Center 
(AMC) in Amsterdam, the Netherlands and conducted at the AMC. The study was registered at the Dutch Trial 
Register (number 2705). For the study from Maastricht the protocol was reviewed and approved by the local 
Medical Ethical Committee of Maastricht University Medical Center+ and registered under ClinicalTrials.gov 
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NCT02241421. All procedures were performed according to the declaration of Helsinki (revised version, 2008, 
Seoul, South Korea).
Study Design. Study measurements were conducted following a 10 h overnight fast. The primary outcome 
of this study was tissue-specific insulin sensitivity (insulin-mediated glucose disposal (Rd)), hepatic insulin sen-
sitivity (insulin-mediated suppression of endogenous glucose production (% suppression EGP)), adipose tissue 
insulin sensitivity (insulin-mediated suppression of plasma free fatty acids (% suppression FFA)) as determined 
by a two-step hyperinsulinemic-euglycemic clamp with [6,6-2H2]-glucose infusion. To this end, one cannula was 
inserted into the antecubital vein, whereas a second Teflon cannula was inserted into a superficial dorsal hand 
vein for blood sampling, which was arterialized by placing the hand into a hot-box, blowing warm air (~50 °C). In 
the Maastricht cohort, after a bolus-injection of 2.4 mg kg−1 was infused, continuous tracer-infusion was started 
at 0.04 mg kg−1 min−1 and continued throughout the measurement. After 2 h, low-dose insulin was infused at 10 
mU m−2 min−1 for 2 h28, followed by high-dose insulin at 40 mU m−2 min−1 for 2 h. By variable co-infusion of a 
17.5%-glucose solution, enriched by 1.1% [6,6−2H2]-glucose-tracer29, plasma concentrations were maintained at 
5.0 mmol/l. In the cohort  from Amsterdam, insulin was infused at 20 mU m-2 min−1 for 2 h, followed by 60 mU 
m−2 min−1 for 2 h30. For calculation of steady-state-kinetics, the last 30 minutes of each step (0, 10 and 40mU m−2 
min−1 insulin) and the last 20 minutes of each step (0, 20 and 60 mU m−2 min−1 insulin), respectively, were used 
for the two cohorts, during which additional blood samples were taken.
In addition, we collected fasting plasma samples to determine insulin and glucose concentrations for the 
calculation of the homeostasis model assessment for insulin resistance (HOMA-IR, [(fasting insulin (μIU/ml) × 
fasting glucose (mmol/l))/22.5)] and β-cell function (HOMA-B, [20 × (fasting insulin)/(fasting glucose – 3.5)]. 
Anthropometrical measurements were performed for the calculation of the body mass index (BMI, [weight (kg)/
height(m)2] and waist/hip ratio.
Biochemical analysis. Blood was collected into pre-chilled tubes, centrifuged at 1000 g, and plasma was 
snap-frozen and stored at −80 °C until analyses. Isotopic enrichment of plasma glucose was determined by elec-
tron ionization gas chromatography–mass spectrometry and expressed as tracer-to-tracer ratio for steady-state 
calculations of rate of disappearance (Rd) and endogenous glucose production (EGP). Plasma glucose and glyc-
erol were determined with the Cobas Fara auto-analyzer, Roche, Switzerland). Plasma insulin was measured with 
a double antibody radioimmunoassay (Millipore, MA, USA), and plasma FFA concentrations were analyzed 
using standard enzymatic techniques automated on a Cobas Fara auto-analyzer (Roche).
Fecal microbiota characterization. The fecal microbiota composition was determined by analyzing 16S 
rRNA gene amplicons using the Human Intestinal Tract Chip Microarray (HITChip); a phylogenetic microarray 
targeting the V1 and V6 hypervariable regions of the 16S rRNA gene of over 1000 intestinal bacterial phylo-
types31. DNA was isolated from faeces using the repeated bead beating method as previously described,32 and 
subsequently used for microbiota profiling. In short, full length 16S rRNA genes were amplified by PCR using 
primers T7prom-Bact-27-for and Uni-1492-rev31, followed by in vitro transcription, Cy3/Cy5 labelling and frag-
mentation of RNA, and hybridization. The signal intensity data from the microarray hybridizations were collected 
from the Agilent G2505C scanner (Agilent Technologies) using the Agilent Feature Extraction software, version 
10.7.3.1 and pre-processed using an in-house MySQL database and custom R scripts. Each scanner channel from 
the array was spatially normalized separately using polynomial regression, followed by outlier detection and 
filtering in each set of probes with a χ2 test. Duplicate hybridizations with a Pearson correlation >98% were 
considered for further analysis, and microbiota profiles were generated by pre-processing of probe-level measure-
ments with min-max normalization and RPA probe summarization33 into three phylogenetic levels: order-like, 
genus-like (>90% sequence similarity), and phylotype-like (>98% sequence similarity)31. In the present study 
the analysis focused on the genus-level variation, referred to as species and relatives (‘et rel.’). Log10-transformed 
signals were used as a proxy for bacterial abundance.
Statistical analysis. To determine the bacterial groups whose relative abundance significantly differed 
between the two cohorts, a non-paired Wilcoxon test was used. We performed Spearman correlations and partial 
Spearman correlations (adjusted for age, BMI and waist/hip ratio) using the ppcor package36 to associate specific 
genus-like bacterial groups with the variables under investigation in both cohorts separately. All outcome varia-
bles were sorted into quartiles. The highest and lowest range were used for logistic regression and Random Forest 
classification using the Random Forest and ROCR R packages34,35. For all analyses Benjamini–Hochberg (BH) 
correction was applied for multiple testing (q-value) and values of q < 0.2 were considered significant. Missing 
data were removed before any analysis. All analyses were performed in R, v3.4.037. Principal component analysis 
was performed in Canoco v538 with log10 transformed signals summarized to genus like groups.
Accession codes. The phylogenetic HITChip microarray data matrix and anonymized subject metadata are 
available: https://doi.org/10.6084/m9.figshare.11341985
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